Nov 2025 $4 M Private placement after listing $2 to $10 million 1
Adial Pharmaceuticals, L.L.C.: Private sale, Nov 2025 × Investors in this round 1 investor had bought by the notice of Dec 3, 2025: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $228,549
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Cary J. Claiborne · Executive Officer, Director · Chief Executive Officer Tony W. Goodman · Executive Officer, Director · Chief Operating Officer Vinay J. Shah · Executive Officer · Chief Financial Officer James K. Anderson · Director James W. Newman, Jr. · Director Kevin W. Schuyler, CFA · Director Robertson H. Gilliland · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round A.G.P./Alliance Global Partners (CRD 000005361) · New York, New York Sold in NY Remarks in the notice On the amounts: “Consists of $0.31 per share that may be received upon future exercise of warrants to purchase up to 13,823,512 shares of common stock.”Signed by Cary J. Claiborne, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 3, 2025. Read the notice at the SEC .
options SEC May 2025 $5 M Private placement after listing $2 to $10 million 1
Adial Pharmaceuticals, L.L.C.: Private sale, May 2025 × Investors in this round 1 investor had bought by the notice of May 14, 2025.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Cary J. Claiborne · Executive Officer, Director · Chief Executive Officer Tony W. Goodman · Executive Officer, Director · Chief Operating Officer Vinay J. Shah · Executive Officer · Chief Financial Officer James K. Anderson · Director James W. Newman, Jr. · Director Kevin W. Schuyler, CFA · Director Robertson H. Gilliland · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round A.G.P./Alliance Global Partners (CRD 000005361) · New York, New York Sold in NY Remarks in the notice On the amounts: “Consists of $0.74 per share that may be received upon future exercise of warrants to purchase up to 6,507,270 shares of common stock.”Signed by Cary J. Claiborne, Chief Executive Officer. Source: SEC Form D, newest notice filed May 14, 2025. Read the notice at the SEC .
options SEC Oct 2023 $4 M Private placement after listing $2 to $10 million 1
Adial Pharmaceuticals, L.L.C.: Private sale, Oct 2023 × Investors in this round 1 investor had bought by the notice of Oct 26, 2023: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $320,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Bankole A. Johnson · Executive Officer Cary J. Claiborne · Executive Officer, Director Joseph M. Truluck · Executive Officer James K. Anderson · Director James W. Newman, Jr. · Director Kevin W. Schuyler, CFA · Director Robertson H. Gilliland · Director Tony W. Goodman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in NY Remarks in the notice On fees: “Includes placement agent fee of 7% & management fee of 1% of the aggregate gross proceeds of the offering. The issuer issued to placement agent designees warrants to purchase up to 85,106 shares at an exercise price of $3.25 and paid offering expenses”On the use of proceeds: “While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.”On a merger: “The Company issued pre-funded warrants, series A warrants and series B warrants , each warrant to purchase one share of common stock”Signed by Cary J. Claiborne, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 26, 2023. Read the notice at the SEC .
equity, options SEC Feb 2022 $10 M Private placement after listing $10 to $50 million 1
Adial Pharmaceuticals, L.L.C.: Private sale, Feb 2022 × Investors in this round 1 investor had bought by the notice of Feb 17, 2022: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $700,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Bankole A. Johnson · Executive Officer Cary W. Claiborne · Executive Officer, Director Joseph M. Truluck · Executive Officer William B. Stilley, III · Executive Officer, Director James K. Anderson · Director James W. Newman, Jr. · Director Kevin W. Schuyler, CFA · Director Robertson H. Gilliland · Director Tony W. Goodman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLC (CRD 120708) · New York, New York Sold in CA, IL, NY Remarks in the notice On fees: “Commission was paid for the securities issued in the registered direct offering”On the amounts: “The Issuer issued securities in a registered direct offering for gross proceeds of approximately $10,000,000 and warrants in a concurrent private placement having an aggregate exercise price of approximately $10,000,000”On the use of proceeds: “While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.”Signed by William B. Stilley, III, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 17, 2022. Read the notice at the SEC .
options SEC Jun 2020 $5 M Private placement after listing $2 to $10 million 6
Adial Pharmaceuticals, L.L.C.: Private sale, Jun 2020 × Investors in this round 6 investors had bought by the notice of Jun 17, 2020: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $365,190
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Bankole A. Johnson · Executive Officer Joseph M. Truluck · Executive Officer William B. Stilley, III · Executive Officer, Director Jack W. Reich · Director James K. Anderson · Director James W. Newman, Jr. · Director Kevin W. Schuyler, CFA · Director Robertson H. Gilliland · Director Tony W. Goodman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLC (CRD 120708) · New York, New York Sold in CA, IL, NY Remarks in the notice On the amounts: “Combined purchase price of 2,820,000 shares of common stock (CS) in a registered direct offering & warrants in private placement to purchase 2,115,000 shares of CS with an exercise price of $2.00 per share.”On the use of proceeds: “While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.”Signed by William B. Stilley, III, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 17, 2020. Read the notice at the SEC .
equity, options SEC Jun 2013 $3 M No. 2 $2 to $10 million 35
Adial Pharmaceuticals, L.L.C.: Raise no. 2, Jun 2013 × Investors in this round 35 investors had bought by the notice of Oct 2, 2013: 35 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered; $0 M still to sell
Smallest investment taken $100,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people $395,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Limited Liability Company, incorporated in Virginia People named in the notice WIlliam Stilley · Executive Officer Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Jim Dada, VP Finance. Source: SEC Form D, newest notice filed Oct 2, 2013. Read the notice at the SEC .
equity SEC Mar 2011 $4 M No. 1 $2 to $10 million 0
Adial Pharmaceuticals, L.L.C.: Raise no. 1, Mar 2011 × Investors in this round 0 investors had bought by the notice of Mar 16, 2011: 0 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken $13,755
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Limited Liability Company, incorporated in Virginia People named in the notice Bankole A Johnson · Executive Officer, Director · Chairman John F Riccardi · Executive Officer, Director · Chief Financial Officer William B Stilley · Executive Officer, Director · Chief Executive Officer Mike L King · Director Ming D Li · Director Robert S Capon · Director Wendy L Yarno · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by John F. Riccardi, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 16, 2011. Read the notice at the SEC .
equity SEC